We are proud to present the 2nd Annual Ophthalmic Drugs Conference
on 26th - 27th November 2018, London, United Kingdom.
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of this market. In fact, the global ophthalmic drug market is projected to reach GBP 30 billion by 2023, growing at a CAGR of 5.3% from 2017 to 2023 (Via *Allied Market Research)
Join industry experts from Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics and more to discuss and analyze the latest advancements and challenges within ophthalmic drug development. Network with industry professionals, explore novel approaches to treatment of ocular diseases, gain insight into ongoing clinical trials, discover how technology is revolutionising pharmaceutical R&D, and get invaluable advice on how to enhance development and overcome challenges within the industry.
Benefits of Attending
Developing on last years success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. Join us to network with ophthalmic experts from top pharmaceutical companies.
Gain insight into...
- The discovery of the first FDA-approved ROCK inhibitor for the treatment of glaucoma
- Non-invasive drug delivery technology for anterior segment ocular disease
- Novel treatments for Glaucoma / Retinoprotection
- Advantages of site-specific biologics for ocular diseases
- Current neuroprotective agents under investigation for the treatment of ocular disease.
- Exploring artificial intelligence in drug discovery
- How to keep up with the ever changing regulatory environment, and to overcome challenges in regulation.
- Gene delivery and gene editing in the retina
Who should attend
Key Job Titles:
Chief, Vice Presidents, Heads, Senior Directors, Directors, Principals, Principal Scientists, Team/ Project Leaders, Clinicians, Clinical Trial Managers, Medical Officers of:
- Ophthalmic devices
- Drug Delivery
- Drug discovery
- Research and development
- Clinical development
- Quality assurance
- Immunology, Inflammation and Allergies
- Market Access
Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday, 28th NovemberWorkshop A: Practical Applications of Artificial Intelligence in Drug Discovery, Development and Clinical Trials
Workshop Leader: Andrew Radin, CEO, twoXAR
08.30 - 12.30 Workshop B: Are Eye Drops the Best Route for Ophthalmic Therapy?
Workshop Leaders: Sunil Shah, Professor, Aston University
Afzal Mohammed, Professor, Aston University
13.30 - 16.50